Venetoclax overcomes resistance to all‐trans retinoic acid in a variant acute promyelocytic leukemia with <i>TNRC18::RARA</i> fusion
Jing Xu, He Li, Zhongwang Wang, Mengyao Wang, Qian Li, Xiaohang Hang, Juan Xu, Jie Ji, Chong Chen, Yu Liu, Ting Niu
Abstract
Acute promyelocytic leukemia (APL) is generally driven by PML::RARA, but approximately 2% of variant APL patients do not contain this fusion gene and pose challenges in diagnosis and treatment. Here, we reported an aggressive APL patient with variant TNRC18::RARA fusion gene, who was resistant to standard differentiation induction therapy consisting of all-trans retinoic acid (ATRA) and arsenic trioxide but achieved complete remission with venetoclax plus ATRA. Mechanistically, venetoclax possesses synergistic effects in ATRA-induced TNRC18::RARA-positive cell differentiation.
Topics & Concepts
Arsenic trioxideAcute promyelocytic leukemiaRetinoic acidVenetoclaxBiologyFusion geneCancer researchTretinoinLeukemiaFusion proteinPromyelocytic leukemia proteinComplete remissionImmunologyGeneGeneticsChemotherapyApoptosisChronic lymphocytic leukemiaRecombinant DNARetinoids in leukemia and cellular processesAcute Myeloid Leukemia ResearchProtein Degradation and Inhibitors